Temporal validation of the SORG 90-Day and 1-Year machine learning algorithms for survival of patients with spinal metastatic disease
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The Skeletal Oncology Research Group machine learning algorithms (SORG-MLA) accurately predict survival in spinal metastasis patients. Temporal validation confirmed its continued performance in contemporary cohorts, suggesting potential for further improvement with model updates.
Area Of Science
- Oncology
- Surgical Oncology
- Machine Learning in Medicine
Background
- Spinal metastatic disease presents a significant challenge in patient management.
- Accurate prediction of postoperative survival is crucial for treatment planning.
- The Skeletal Oncology Research Group machine learning algorithms (SORG-MLA) were previously developed for survival prediction.
Purpose Of The Study
- To perform temporal validation of the SORG-MLA using a contemporary patient cohort.
- To assess the continued performance of SORG-MLA in predicting 90-day and 1-year postoperative survival.
- To evaluate the applicability of SORG-MLA in the context of evolving treatment strategies for spinal metastases.
Main Methods
- Retrospective cohort study of 464 patients surgically treated for spinal metastases (January 2017 - July 2021).
- Collected 18 input variables including primary tumor type, ECOG Performance Status, and preoperative laboratory values.
- Assessed model performance using calibration, discrimination (AUC), Brier score, and decision curve analysis.
Main Results
- The validation cohort differed from the development cohort in several variables.
- SORG-MLA demonstrated robust performance in calibration and discrimination (90-day AUC: 0.81, 1-year AUC: 0.75).
- Brier score and decision curve analyses further supported the model's predictive accuracy.
Conclusions
- SORG-MLA maintains good performance for predicting survival in spinal metastasis patients, even with temporal validation.
- Despite advancements in treatment, the model's predictive capability remains relevant.
- Future improvements may be achieved by updating models with contemporary data and stratifying by primary tumor type.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...